Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. 1996

J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
Department of Radiation, University of Washington Medical Center, Seattle 98195-6043, USA.

OBJECTIVE To examine the efficacy of fast neutron radiotherapy for the treatment of patients with locally advanced, adenoid cystic carcinoma of minor salivary glands and to identify prognostic variables associated with local control, overall survival, and cause specific survival. METHODS Eighty-four patients having adenoid cystic carcinoma of minor salivary glands were treated with fast neutron radiotherapy during the years 1985-1994. All patients had either unresectable disease or gross disease remaining after attempted surgical extirpation. Seventeen patients had previously received conventional radiotherapy and their subsequent treatment fields and doses for neutron radiotherapy were modified for critical sites (brainstem, spinal cord, brain). Although the median doses (tumor maximum and tumor minimum) only varied by < or = 10%, treatment portals were substantially smaller in these patients because of normal tissue complication considerations. Twelve patients (13%) had distant metastases at the time of treatment and were only treated palliatively with smaller treatment portals and lower median tumor doses (< or = 80% of the doses delivered to curatively treated patients). Seventy-two patients were treated with curative intent, with nine of these having recurrent tumors after prior full-dose radiotherapy. The median duration of follow-up at the time of analysis was 31.5 months (range 3-115). Sites of disease and number of patients treated per disease site were as follows: paranasal sinus-31; oral cavity-20; oropharynx-12; nasopharynx-11; trachea-6; and other sites in the head and neck-4. RESULTS The 5-year actuarial local-regional tumor control rate for all patients treated with curative intent was 47%. Patients without involvement of the cavernous sinus, base of skull, or nasopharynx (51 patients) had a 5-year actuarial local-regional control rate of 59%, whereas local-regional control was significantly lower (15%) for patients with tumors involving these sites (p < 0.005). In the latter cases, normal tissue injury considerations precluded delivery of the full dose to the entire tumor. Patients with no history of prior radiotherapy (63 patients) had an actuarial local control rate of 57% at 5 years compared to 18% for those (9 patients) who had been previously irradiated with conventional photons (p = 0.018). Eliminating the dose-limiting factors of prior radiation therapy and/or high risk sites of involvement, the 5-year actuarial local-regional control rate for these 46 patients was 63%, with an actuarial cause specific survival rate of 79%. Lymph node status was a predictor of distant metastasis: 57% of node positive patients developed distant metastases by 5 years compared to 15% of patients with negative nodes (p < 0.0005), and patients who had nodal involvement developed distant metastases sooner than node negative patients (p < 0.0001). The 5-year actuarial overall survival and cause specific survival for the 72 patients treated with curative intent were 59% and 64%, respectively. CONCLUSIONS Fast neutron radiotherapy offers high local-regional control and survival rates for patients with locally advanced, unresectable adenoid cystic carcinomas of minor salivary glands. It should be considered as initial primary treatment for these patients, as well as for other patients in whom surgical extirpation would cause considerable morbidity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009502 Neutrons Electrically neutral elementary particles found in all atomic nuclei except light hydrogen; the mass is equal to that of the proton and electron combined and they are unstable when isolated from the nucleus, undergoing beta decay. Slow, thermal, epithermal, and fast neutrons refer to the energy levels with which the neutrons are ejected from heavier nuclei during their decay. Neutron
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003528 Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed) Cylindroma,Adenocystic Carcinoma,Adenocystic Carcinomas,Adenoid Cystic Carcinoma,Adenoid Cystic Carcinomas,Carcinoma, Adenocystic,Carcinomas, Adenocystic,Carcinomas, Adenoid Cystic,Cylindromas,Cystic Carcinoma, Adenoid,Cystic Carcinomas, Adenoid
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
August 1980, Delaware medical journal,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
November 2008, Oral oncology,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
April 1991, Ear, nose, & throat journal,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
January 1977, The Journal of laryngology and otology,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
July 2006, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
December 1971, American journal of surgery,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
January 1967, Journal of oral surgery (American Dental Association : 1965),
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
January 1999, Acta otorrinolaringologica espanola,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
October 2010, Auris, nasus, larynx,
J G Douglas, and G E Laramore, and M Austin-Seymour, and W J Koh, and K L Lindsley, and P Cho, and T W Griffin
June 2024, Expert review of anticancer therapy,
Copied contents to your clipboard!